Experimental cholesterol drug halves heart attack and stroke

September 1, 2014 12:41 PM

2 0

An experimental cholesterol-lowering drug from Regeneron Pharmaceuticals and Sanofi has reduced half the number of strokes and heart attacks in a clinical trial, according to researchers.

However, the result of the trial is not decisive, because the analysis was done retrospectively, but the research provides the first proof that targeting a protein called PCSK9 can reduce cardiovascular risks for numerous patients across the world.

Also read: Family, friends remember Denton Cooley at memorial service

Read more

To category page

Loading...